Previous close | 5.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 94,908 |
Market cap | 42.444M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.80 |
Earnings date | 29 Sept 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 61.67 |
Allergy Therapeutics plc ( LON:AGY ) shareholders might be concerned after seeing the share price drop 25% in the last...
The big shareholder groups in Allergy Therapeutics plc ( LON:AGY ) have power over the company. Institutions often own...
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focused on high value growth products to enhance future profitabilityGround-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipatedPivotal Phase III trial of short-cou